Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Impact of Dapagliflozin for the Regulation of Immunological Activity in Membranous Nephropathy
NCT07096986Phase 2Not yet recruiting
- Sponsor
- Centre Hospitalier Universitaire de Nice
- Start
- Nov 2026
- Primary completion
- Nov 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of dapagliflozin in membranous nephropathy (MN), sponsored by Centre Hospitalier Universitaire de Nice. Planned start Nov 2026; status: not yet recruiting.
02
Drugs
dapagliflozin
03
Conditions
membranous nephropathy (MN)
Beyond the preview
Go deeper on NCT07096986.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07096986.